Literature DB >> 11012750

Disparate effects of phorbol esters, CD3 and the costimulatory receptors CD2 and CD28 on RANTES secretion by human T lymphocytes.

Y Sotsios1, P J Blair, J Westwick, S G Ward.   

Abstract

This study has examined the stimuli required for secretion of regulated upon activation, normal T-cell expressed, presumed secreted (RANTES) from T lymphocytes and found that stimuli such as phorbol 12-myristate 13-acetate (PMA), which are unable to support T-cell proliferation and interleukin-2 (IL-2) production, are nevertheless able to elicit strong secretion of RANTES. Conversely, stimuli such as CD2 and CD28 ligation, which are able to support T-cell proliferation, are unable to elicit RANTES secretion. Coligation of CD3 and CD28 drives T-cell proliferation to a similar degree as CD2 and CD28 coligation, yet also supports modest RANTES secretion. Furthermore, CD28 ligation enhances the secretion of RANTES stimulated by PMA and this costimulatory effect is abrogated by the phosphoinositide 3-kinase inhibitor wortmannin. Our data also indicate that the observed effects of PMA on RANTES secretion are probably due to activation of protein kinase C (PKC) isoenzymes, since RANTES secretion was unaffected by the non-PKC activating 4alpha-phorbol ester, whilst the general PKC inhibitor Ro-32-0432 inhibits PMA-stimulated RANTES secretion. Moreover, the effect of PMA appears to be chemokine-specific because PMA was unable to increase secretion of the related CC chemokine MIP-1alpha. Under stimulation conditions where increases in [Ca2+]i occur (e.g. PMA plus ionomycin or CD3 plus CD28 ligation) RANTES secretion can be severely reduced compared with the levels observed in response to the phorbol ester PMA. Hence, whilst PKC-dependent pathways are sufficient for strong RANTES secretion, a calcium-dependent factor is activated which negatively regulates RANTES secretion. This correlates well with the observation that ligation of cytolytic T lymphocyte-associated antigen-4 (CTLA-4) (expression of which has been reported to be dependent on a sustained calcium signal), inhibits RANTES secretion induced by CD3/CD28, but has no effect on PMA-stimulated RANTES secretion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012750      PMCID: PMC2327056          DOI: 10.1046/j.1365-2567.2000.00072.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  45 in total

1.  CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.

Authors:  G J Freeman; D B Lombard; C D Gimmi; S A Brod; K Lee; J C Laning; D A Hafler; M E Dorf; G S Gray; H Reiser
Journal:  J Immunol       Date:  1992-12-15       Impact factor: 5.422

2.  Contributions of the CD2 and CD28 T lymphocyte activation pathways to the regulation of the expression of the colony-stimulating factor (CSF-1) gene.

Authors:  C Cerdan; D Razanajaona; Y Martin; M Courcoul; C Pavon; C Mawas; D Olive; F Birg
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

3.  Activation of human T lymphocytes via the CD2 antigen results in tyrosine phosphorylation of T cell antigen receptor zeta-chains.

Authors:  E Monostori; D Desai; M H Brown; D A Cantrell; M J Crumpton
Journal:  J Immunol       Date:  1990-02-01       Impact factor: 5.422

4.  CD2 antigen mediated activation of the guanine nucleotide binding proteins p21ras in human T lymphocytes.

Authors:  J D Graves; J Downward; S Rayter; P Warne; A L Tutt; M Glennie; D A Cantrell
Journal:  J Immunol       Date:  1991-06-01       Impact factor: 5.422

5.  The T cell receptor/CD3 complex and CD2 stimulate the tyrosine phosphorylation of indistinguishable patterns of polypeptides in the human T leukemic cell line Jurkat.

Authors:  S C Ley; A A Davies; B Druker; M J Crumpton
Journal:  Eur J Immunol       Date:  1991-09       Impact factor: 5.532

6.  IL-1 alpha is produced by T lymphocytes activated via the CD2 plus CD28 pathways.

Authors:  C Cerdan; Y Martin; H Brailly; M Courcoul; S Flavetta; R Costello; C Mawas; F Birg; D Olive
Journal:  J Immunol       Date:  1991-01-15       Impact factor: 5.422

Review 7.  The structural biology of CD2.

Authors:  P Moingeon; H C Chang; P H Sayre; L K Clayton; A Alcover; P Gardner; E L Reinherz
Journal:  Immunol Rev       Date:  1989-10       Impact factor: 12.988

8.  Evidences for protein kinase C. Activation in T lymphocytes by stimulation of either the CD2 or CD3 antigens.

Authors:  B Friedrich; D A Cantrell; M Gullberg
Journal:  Eur J Immunol       Date:  1989-01       Impact factor: 5.532

9.  Regulation of D-3 phosphoinositides during T cell activation via the T cell antigen receptor/CD3 complex and CD2 antigens.

Authors:  S G Ward; S C Ley; C MacPhee; D A Cantrell
Journal:  Eur J Immunol       Date:  1992-01       Impact factor: 5.532

10.  The CD2 ligand LFA-3 activates T cells but depends on the expression and function of the antigen receptor.

Authors:  L K Bockenstedt; M A Goldsmith; M Dustin; D Olive; T A Springer; A Weiss
Journal:  J Immunol       Date:  1988-09-15       Impact factor: 5.422

View more
  3 in total

1.  Effect of Mycobacterium bovis BCG vaccination on interleukin-1 beta and RANTES mRNA expression in guinea pig cells exposed to attenuated and virulent mycobacteria.

Authors:  Amminikutty Jeevan; Teizo Yoshimura; Gregory Foster; David N McMurray
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

2.  Aggregation-independent modulation of proteoglycan binding by neutralization of C-terminal acidic residues in the chemokine macrophage inflammatory protein 1alpha.

Authors:  K Ottersbach; G J Graham
Journal:  Biochem J       Date:  2001-03-01       Impact factor: 3.857

3.  Transcriptome analysis of Sézary syndrome and lymphocytic-variant hypereosinophilic syndrome T cells reveals common and divergent genes.

Authors:  Andrea M Moerman-Herzog; Daniel A Acheampong; Amanda G Brooks; Suzan M Blair; Ping-Ching Hsu; Henry K Wong
Journal:  Oncotarget       Date:  2019-08-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.